NYSE:NGVTIngevity Stock Price, Forecast & News

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NGVT shares have increased by 34.7% and is now trading at $52.28. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ingevity.

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Ingevity.

Ingevity will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ingevity Corp (NYSE:NGVT) issued its quarterly earnings data on Wednesday, April, 29th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.84 by $0.28. The company had revenue of $288.20 million for the quarter, compared to analysts' expectations of $263.61 million. Ingevity had a return on equity of 45.48% and a net margin of 15.82%. Ingevity's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.99 earnings per share. View Ingevity's earnings history.

Ingevity updated its second quarter 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $246.96-264.6 million, compared to the consensus revenue estimate of $325.64 million.

7 Wall Street analysts have issued 1-year target prices for Ingevity's shares. Their forecasts range from $42.00 to $107.00. On average, they anticipate Ingevity's share price to reach $73.14 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View analysts' price targets for Ingevity.

Headlines about NGVT stock have trended negative recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ingevity earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Ingevity.

Ingevity saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,400,000 shares, a decline of 11.4% from the June 15th total of 1,580,000 shares. Based on an average daily volume of 516,700 shares, the short-interest ratio is currently 2.7 days. Approximately 3.4% of the company's shares are sold short. View Ingevity's Current Options Chain.

Some companies that are related to Ingevity include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), SHOWA DENKO KK/ADR (SHWDY), W. R. Grace & Co (GRA), Balchem (BCPC), Univar (UNVR), Chemours (CC), Innospec (IOSP), PQ Group (PQG), Olin (OLN), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), Dominion Energy (D), General Electric (GE), Quaker Chemical (KWR), Boeing (BA), Alibaba Group (BABA) and Walt Disney (DIS).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Katherine Pryor Burgeson, Michael P Smith, Phillip John Platt and Richard B Kelson. View institutional ownership trends for Ingevity.

NGVT stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson. View insider buying and selling activity for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $52.28.

Ingevity has a market capitalization of $2.15 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,850 workers across the globe.

The official website for Ingevity is www.ingevity.com.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]